πŸ‡ΊπŸ‡Έ FDA
Patent

US 7189393

Recombinant anti-tumor RNAse

granted A61KA61K38/00A61K47/6815

Quick answer

US patent 7189393 (Recombinant anti-tumor RNAse) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Mar 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Mar 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00, A61K47/6815